I wonder which one of the companies bellow might be the potential JV partner:

• 3M
• Acelity
• Alliqua BioMedical
• Anika Therapeutics
• Avita Medical
• Changchun JA Biotech
• Coloplast
• Convatec
• Daewoong Pharmaceutical
• Derma Sciences
• Devon Medical Products
• EdixoMed
• ER Squibb & Sons
• Forticell Bioscience
• Fraunhofer Institute
• Genadyne
• Genewel
• Genzyme
• Hartmann
• Healthpoint
• Histocell
• Human BioScience
• Innocoll
• Innovative Therapies
• Integra Life Science
• Kaken Parmaceuticals
• Lescarden
• LifeCell
• Lightwave Technologies
• Luqa Pharmaceuticals
• MacroCure
• Medela
• MediWound
• Medline
• Medtronic
• MiMedX
• Misonix
• Mölnlycke
• Mo-Sci Corporation
• Mundipharma
• Nanotherapeutics
• Nordic Capital Partners
• Nuo Therapeutics
• Organogenesis
• Osiris Therapeutics
• Politec Saúde
• Prizm Medical
• Promethean
• Prospera
• Sanuwave Health
• Shandong Wego Newlife Medical Devices
• Shire
• Smith & Nephew
• Soring
• Spiracur
• Synapse Microcurrent
• Systagenix
• Talley Group
• TEI Biosciences
• Urgo
• Vario
• Vomaris Innovations
• Winner Medical Group
• Wound Management Technologies
• Zhejiang Top Medicals

Here is my take on the impeding deal, if a nobody twitter guy knew about it, that means other people with big pockets/insiders have even more/better intel. Yet, there hasn't been any accumulation lately (only conversion, albeit on a small scale). What does that tell you? Perhaps Gerald can clue us in If he re-tweets "0 to 100 real quick" Happy Independence Day to all!!